Skip to main content

Oncology news

13-11-2017 | Oncology | Highlight | Article

Editor's pick

Long-term breast cancer recurrence risk linked to original TN status

The risk for breast cancer recurrence increases at a steady rate for at least 15 years after the end of planned endocrine therapy and is strongly associated with the original tumor diameter and nodal status, meta-analysis data show.


N Engl J Med 2017; 377: 1836–1846

17-11-2017 | Oncology | News | Article


Dasatinib receives pediatric CML go-ahead

Read more on this US FDA approval here

16-11-2017 | Colorectal cancer | News | Article

Mismatch repair deficiency testing underused for CRC patients in USA

Researchers have warned that underuse of mismatch repair deficiency testing “is a persistent and pervasive problem” in the USA, even among young adults with colorectal cancer where its use is unequivocally recommended.


JAMA Oncol 2017; Advance online publication

15-11-2017 | Oncology | News | Article

No survival benefit with olaparib plus paclitaxel in advanced gastric cancer

Adding olaparib to paclitaxel does not improve survival among Asian patients with advanced gastric cancer that has progressed during or after first-line therapy, show results of the phase III GOLD trial.


Lancet Oncol 2017; Advance online publication

15-11-2017 | Oncology | News | Article


FDA approvals granted for brentuximab, letermovir

Read more on these announcements here

Duloxetine May Help Relieve AI-Related Musculoskeletal Side Effects

Early-stage breast cancer patients who experience arthralgia symptoms during aromatase inhibitor therapy may benefit from duloxetine treatment Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

approvalsWatch: Oncology

ESMO 2016 coverage


medwireNews brings you news and conference reports from the ESMO 2016 Congress, held in Copenhagen, Denmark.

Click through to read the full reports of the latest research.

Twitter Icon Follow medwireNews

Click here
image credits